- Home
- NDRA vs CANF Comparison
NDRA vs CANF Comparison
Compare NDRA & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NDRA | CANF |
|---|---|---|
| Founded | 2007 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 6.7M |
| IPO Year | 2016 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NDRA | CANF |
|---|---|---|
| Price | $5.43 | $3.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $30.00 | ★ $50.00 |
| AVG Volume (30 Days) | 11.4K | ★ 19.8K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.96 | $0.17 |
| 52 Week High | $9.83 | $10.40 |
Technical Indicators
Market Signals| Indicator | NDRA | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 51.76 |
| Support Level | $4.72 | $2.87 |
| Resistance Level | $6.08 | $3.59 |
| Average True Range (ATR) | 0.32 | 0.13 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 86.34 | 41.18 |
Price Performance
Historical ComparisonAbout NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of thermo-acoustic enhanced ultrasound (TAEUS) technology to improve the capabilities of clinical diagnostic ultrasound. The company's technology is used to measure tissue composition, including the assessment of fat in the liver, and is being developed for additional clinical applications such as tissue temperature monitoring.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.